Get the Stockscreener App
0.975
0.67%
0.0065
Cellectis Adr stock is traded at $0.975, with a volume of 129.35K.
It is up +0.67% in the last 24 hours and down -37.50% over the past month.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
See More
Previous Close:
$0.9685
Open:
$0.97
24h Volume:
129.35K
Relative Volume:
0.89
Market Cap:
$98.21M
Revenue:
$68.15M
Net Income/Loss:
$-67.60M
P/E Ratio:
-1.4477
EPS:
-0.6735
Net Cash Flow:
$-41.80M
1W Performance:
-11.76%
1M Performance:
-37.50%
6M Performance:
-75.50%
1Y Performance:
-72.84%
1-Day Range:
$0.9177
$1.0099
1-Week Range:
$0.8808
$1.08
52-Week Range:
$0.8808
$5.45
Cellectis Adr Stock (CLLS) Company Profile
Compare CLLS vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLLS
Cellectis Adr
|
0.975 | 98.21M | 68.15M | -67.60M | -41.80M | -0.6735 |
VRTX
Vertex Pharmaceuticals Inc
|
535.17 | 135.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
819.09 | 84.33B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
202.63 | 80.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
875.76 | 55.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
382.27 | 43.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-26 | Downgrade | Barclays | Overweight → Underweight |
| Sep-15-26 | Downgrade | Citizens | Mkt Outperform → Mkt Perform |
| May-28-26 | Initiated | Barclays | Overweight |
| Feb-17-26 | Resumed | Jefferies | Buy |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| May-18-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-06-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-08-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-28-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-16-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-19-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Robert W. Baird | Outperform |
| Mar-06-20 | Downgrade | Goldman | Neutral → Sell |
| Oct-30-19 | Resumed | Guggenheim | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| May-24-19 | Resumed | Citigroup | Neutral |
| Mar-14-19 | Initiated | William Blair | Outperform |
| Dec-19-18 | Initiated | Goldman | Neutral |
| Jul-16-18 | Initiated | Barclays | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Sep-05-17 | Downgrade | SunTrust | Buy → Hold |
| Sep-05-17 | Reiterated | Wells Fargo | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Feb-28-17 | Initiated | Wells Fargo | Outperform |
| Apr-05-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
| Jul-20-15 | Initiated | BofA/Merrill | Buy |
| Apr-20-15 | Initiated | Jefferies | Buy |
| Apr-20-15 | Initiated | Piper Jaffray | Overweight |
View All
Cellectis Adr Stock (CLLS) Latest News
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - GlobeNewswire Inc.
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A.CLLS - PR Newswire
CLLS Q2 2026 Earnings: Narrower-Than-Expected Loss as Shares Edge LowerOne-Time Gain Impact - https://www.dars.gov.et/
DBV Technologies S.A. (DBV.PA) Stock Price, News, Quote & History - Yahoo! Finance Canada
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A.CLLS - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS - FinancialContent
Cellectis (CLLS) Down -4.73%: Where Will the Bottom Form? 2026-09-29Undervalued Stocks - siam.in
Cellectis (CLLS) Down -4.73%: Where Will the Bottom Form? 2026-09-29Order Block - https://www.dars.gov.et/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A.CLLS - PR Newswire
Cellectis S.A. (CLLS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cellectis S.A.(ENXTPA: ALCLS) added to S&P Global BMI Index - marketscreener.com
Cellectis Shares Fall After Realigning Focus to Become in Vivo Gene Editing Company - marketscreener.com
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company - marketscreener.com
Cellectis organise une conférence téléphonique et un webcast le 14 septembre pour présenter un point d’activité - GlobeNewswire Inc.
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence. See Exactly How Gilead, Cellectis, MediGene, GenScript, and CARsgen Are Positioned to Win Through 870+ Rivals - GlobeNewswire Inc.
Cellectis (NASDAQ:CLLS): Is Its Latest Rally More Than Technical? - Kalkine Media
European ADRs Edged Higher As Biotech Led The Pack - Finimize
Cellectis (CLLS) Levels: Ends Higher by 9.46% at $3.47; Key Range: the Price Remains Bounded by the Supplied Support and Resistance for the Current SessionHedge Fund Favorites - siam.in
Cellectis (CLLS) Levels: Ends Higher by 9.46% at $3.47; Key Range: the Price Remains Bounded by the Supplied Support and Resistance for the Current SessionUnusual Call Volume - dars.gov.et
Cellectis (CLLS) Levels: Ends Higher by 9.46% at $3.47; Key Range: the Price Remains Bounded by the Supplied Support and Resistance for the Current SessionFactor Rotation - careplusvn.com
Cellectis (CLLS) Levels: Ends Higher by 9.46% at $3.47; Key Range: the Price Remains Bounded by the Supplied Support and Resistance for the Current SessionHull Moving Average - dars.gov.et
Cellectis (CLLS) Earnings Comparison: EPS Exceeds Its Estimate in the Latest Reading; Reported Share Move - careplusvn.com
CLLS Q2 2026 Earnings: Narrower-than-Expected Loss of -$0.22 Surpasses Estimates; Shares Rise 1.97%Earnings Outlook Update - careplusvn.com
Cellectis (CLLS) Earnings Comparison: EPS Exceeds Its Estimate in the Latest Reading; Reported Share Move - www.dars.gov.et
Cellectis (CLLS) Surges 7.25% to $3.18 as Bullish Momentum BuildsIV Spike - dars.gov.et
Cellectis (CLLS) Surges 7.25% to $3.18 as Bullish Momentum BuildsRetail Driven Moves - careplusvn.com
Cellectis (CLLS) Surges 7.25% to $3.18 as Bullish Momentum BuildsNarrow Range Breakout - siam.in
CLLS Q2 2026 Earnings: Loss Narrows to $0.22 per Share, Beating Estimates by 20.89%Geographic Revenue Trends - careplusvn.com
CLLS Q2 2026 Earnings: Loss Narrows to $0.22 per Share, Beating Estimates by 20.89%Quarterly Profit Report - dars.gov.et
CLLS Q2 2026 Earnings: Loss Narrows to $0.22 per Share, Beating Estimates by 20.89%Guidance vs Actual - www.dars.gov.et
CLLS Q2 2026 Earnings: Loss Narrows to $0.22 per Share, Beating Estimates by 20.89%Consensus Miss Rate - dars.gov.et
Cellectis earnings beat by $0.04, revenue fell short of estimates - Investing.com
Cellectis Reports Financial Results for the Second Quarter 2026 - Barchart.com
Cellectis (CLLS) Slips 1.79% to $2.75 as Gene-Editing Stock Tests Key Technical LevelsLiquidity Sweep - careplusvn.com
Cellectis S.A. Sponsored ADR Revenue Breakdown – LS:A14QZE - TradingView
European ADRs Traded Higher In US Morning Session - Finimize
CLLS Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline, but Shares Edge LowerEarnings Season Review - careplusvn.com
ETFs Investing in Cellectis S.A. Sponsored ADR Stocks - TradingView
Multiple Myeloma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida Therapeutics - Barchart.com
European ADRs Jumped As Biotech Led The Pack - Finimize
Cellectis S.A. Sponsored ADR Financial Disclosures & SEC Filings - TradingView
Cellectis S.A. Sponsored ADR Financial Disclosures & SEC Filings - TradingView
European ADRs Rose As Biopharma Names Led The Pack - Finimize
A14QZE Forecast — Price Target — Prediction for 2027 - TradingView
Cellectis S.A. Sponsored ADR Actuals & Estimates (NASDAQ:CLLS) - TradingView
European ADRs Slip, Even As Biotech Names Edge Higher - Finimize
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress - Barchart.com
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress - GlobeNewswire Inc.
Cellectis Adr Stock (CLLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
3.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):